Table 4 IGF-I/IGFBP3 RatioSDS during GH treatment according to randomization group

At GH start

71

−1 ± 1.08

32

−1.1 ± 0.94

20

−0.8 ± 1.24

19

−0.8 ± 1.13

−0.8 ± 1.17

1^st year after GH start

76

0.6 ± 1.2

28

0.5 ± 1.21

24

0.6 ± 1.31

24

0.7 ± 1.13

0.6 ± 1.21

ΔRatio_SDS 1^st year after GH start

63

1.5 ± 1.24

25

1.6 ± 1.25

19

1.2 ± 1.6

19

1.6 ± 0.74

1.4 ± 1.24

Prepubertal level

100

0.4 ± 0.95

37

0.2 ± 0.98

30

0.5 ± 0.97

33

0.6 ± 0.89

0.6 ± 0.92

Last pre-pubertal

90

0.7 ± 1.18

35

0.5 ± 1.11

28

0.6 ± 1.24

27

1 ± 1.17

0.8 ± 1.22

Study start

104

0.5 ± 0.98

38

0.6 ± 0.99

30

0.3 ± 1.06

36

0.6 ± 0.89

0.5 ± 0.97

1^st year after study start

100

0.9 ± 0.87

36

0.6 ± 0.87

30

0.9 ± 0.86

34

1.2 ± 0.78^*

1.1 ± 0.83^**

ΔRatio_SDS 1^st year after study start

100

0.4 ± 0.93

36

0 ± 0.95

30

0.6 ± 1.03

34

0.6 ± 0.73^****

0.6 ± 0.87^***

Pubertal level

104

0.9 ± 0.78

38

0.7 ± 0.74

30

0.9 ± 0.82

33

1 ± 0.78

0.9 ± 0.79

ΔRatio_SDS Pubertal level from study start

104

0.3 ± 0.89

38

0.1 ± 0.92

30

0.6 ± 1.04

36

0.3 ± 0.66

0.5 ± 0.86

Before study stop

104

0.5 ± 1.1

38

0.5 ± 0.88

30

0.7 ± 1.14

36

0.3 ± 1.26

0.5 ± 1.21

After study stop

64

−0.7 ± 1.03

23

−0.9 ± 0.73

17

−0.7 ± 1.18

24

−0.5 ± 1.16

−0.6 ± 1.16